Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.

Cancer research - 1 Oct 2012

Hantschel Oliver, Grebien Florian, Superti-Furga Giulio

Abstract excerpt

The BCR-ABL fusion kinase is the driving mutation of chronic myelogenous leukemias and is also expressed in a subset of acute lymphoblastic leukemias. Recent advances in elucidating the structure, regulation, and signaling of BCR-ABL have led to the identification of allosteric sites that are distant from the ATP-binding pocket and are critical for BCR-ABL-dependent oncogenic transformation. Here, we review the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Allosteric Site
Share to Binding, Competitive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Models, Molecular

Share to Protein Binding

Share to Protein Kinase Inhibitors

Share to Protein Structure, Tertiary

Source

Open in PubMed Open full text

Identifiers

PMID: 23002203
DOI: 10.1158/0008-5472.CAN-12-1276
PMCID: PMC3517953

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.PMID 23002203Read ↗

Structure, Regulation, Signaling, and Targeting of Abl Kinases in CancerSemantic proximity Read ↗

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.Semantic proximity Read ↗

New insights into small‐molecule inhibitors of Bcr‐AblSemantic proximity Read ↗

Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignanciesSemantic proximity Read ↗

Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and BeyondSemantic proximity Read ↗

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.Semantic proximity Read ↗

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacySemantic proximity Read ↗

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human LeukemiaSemantic proximity Read ↗

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemiaSemantic proximity Read ↗

Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.Semantic proximity Read ↗

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.